伴严重出血表型的中度血友病A和B患者疾病负担增加
本研究为第六次荷兰血友病研究的子研究,分析116例中度血友病A或B成人患者,按出血表型分为严重与轻度两组并结合凝血酶生成谱评估疾病负担。严重表型按需治疗者中位年出血率7、年关节出血率3、关节受损77%,均高于严重表型预防治疗者(2、0、70%)和轻度表型者(0、0、47%),生活质量更差,凝血酶峰值和潜力更低。
要点
- 116例中度血友病患者中21%为严重表型,其中46%使用预防治疗。
- 严重表型按需治疗者中位年出血率7、年关节出血率3,关节受损77%。
- 严重表型者凝血酶峰值和潜力(0.7%;0.06%)低于轻度表型者(21.3%;46.8%)。
核心结论
- 中度血友病严重表型按需治疗者疾病负担高且凝血酶生成谱低,作者认为这支持对其采用更密集的预防治疗。
研究设计与样本
- 第六次荷兰血友病研究的子研究,分析116例中度血友病A或B成人患者,数据来自电子病历和自报问卷,凝血酶生成用Nijmegen止血法测定。
主要发现
- 严重表型按需治疗者中位年出血率7、年关节出血率3、关节受损77%,高于严重表型预防治疗者(2;0;70%)和轻度表型者(0;0;47%)。
- 严重表型按需治疗者生活质量更差。
- 尽管凝血因子活性水平相似,严重表型者凝血酶峰值和潜力(0.7%;0.06%)低于轻度表型者(21.3%;46.8%)。
关键数值与推荐
- 严重出血表型定义为年出血率≥5、年关节出血率≥3和/或使用二级/三级预防治疗,轻度表型为相反情况。
- 116例患者中21%为严重表型,其中46%使用预防治疗。
临床怎么用
- 作者认为严重表型按需治疗者应接受更密集的预防治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with moderate hemophilia express varying bleeding phenotypes. OBJECTIVES: To assess the burden of disease in patients with moderate hemophilia and a mild or severe phenotype incorporating the thrombin generation profile. METHODS: This sub-study of the 6th Hemophilia in the Netherlands study, analyzed data of adults with moderate hemophilia A or B. Patient characteristics and information on bleeding tendency, joint status, and quality of life were obtained from electronic patient files and self-reported questionnaires. A severe bleeding phenotype was defined as an annual bleeding rate ≥5, an annual joint bleeding rate ≥3, and/or the use of secondary/tertiary prophylaxis, and a mild phenotype vice versa. TG was measured with the Nijmegen Hemostasis Assay. RESULTS: This study included 116 patients: 21% had a severe phenotype of whom 46% used prophylaxis. Patients with a severe phenotype treated on demand reported a higher median annual bleeding rate (7), annual joint bleeding rate (3), and more frequently an impaired joint (77%) than patients with a severe phenotype on prophylaxis (2; 0; 70%) or patients with a mild phenotype (0; 0; 47%). Furthermore, patients with a severe phenotype treated on demand experienced a more decreased quality of life. Despite similar factor activity levels, patients with a severe phenotype had a lower thrombin peak height and thrombin potential (0.7%; 0.06%) than patients with a mild phenotype (21.3%; 46.8%). CONCLUSION: Patients with moderate hemophilia and a severe phenotype treated on demand displayed a high burden of disease as well as a low thrombin generation profile advocating them toward more intensive prophylactic treatment.
引用
- Verhagen MJA, van Balen EC, Blijlevens NMA, et al. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease. J Thromb Haemost. 2023. PMID: 37813197. doi:10.1016/j.jtha.2023.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。